Cooper Companies (NYSE:COO) had its price objective hoisted by equities researchers at Piper Jaffray Companies from $330.00 to $360.00 in a note issued to investors on Tuesday, The Fly reports. The firm currently has an “overweight” rating on the medical device company’s stock. Piper Jaffray Companies’ price target would suggest a potential upside of 8.19% from the stock’s current price.
COO has been the topic of several other research reports. Wells Fargo & Co boosted their price target on shares of Cooper Companies from $356.00 to $365.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Northcoast Research reiterated a “buy” rating and set a $340.00 price target (up previously from $331.00) on shares of Cooper Companies in a research report on Monday, June 3rd. Raymond James boosted their price target on shares of Cooper Companies from $325.00 to $364.00 and gave the company an “outperform” rating in a research report on Tuesday, July 2nd. Finally, Zacks Investment Research upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating and set a $336.00 price target on the stock in a research report on Friday, June 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $322.91.
Shares of NYSE:COO opened at $332.74 on Tuesday. Cooper Companies has a 12 month low of $228.65 and a 12 month high of $344.32. The company has a current ratio of 1.21, a quick ratio of 0.68 and a debt-to-equity ratio of 0.42. The company’s 50-day moving average price is $334.02. The company has a market capitalization of $16.48 billion, a P/E ratio of 28.93, a price-to-earnings-growth ratio of 2.52 and a beta of 0.90.
Cooper Companies (NYSE:COO) last announced its quarterly earnings results on Thursday, May 30th. The medical device company reported $2.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.76 by $0.18. Cooper Companies had a net margin of 16.46% and a return on equity of 17.25%. The company had revenue of $654.30 million for the quarter, compared to analysts’ expectations of $655.00 million. During the same quarter in the previous year, the company earned $2.86 earnings per share. Cooper Companies’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, equities research analysts expect that Cooper Companies will post 12.28 earnings per share for the current fiscal year.
In other Cooper Companies news, Director Gary S. Petersmeyer sold 355 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $323.92, for a total value of $114,991.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Randal Golden sold 1,154 shares of the company’s stock in a transaction dated Wednesday, June 19th. The stock was sold at an average price of $328.16, for a total transaction of $378,696.64. Following the completion of the sale, the vice president now owns 1,148 shares in the company, valued at approximately $376,727.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 77,678 shares of company stock worth $25,063,536. Corporate insiders own 1.70% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. Ossiam purchased a new stake in Cooper Companies in the second quarter worth about $25,000. Flagship Harbor Advisors LLC grew its holdings in Cooper Companies by 62.5% in the second quarter. Flagship Harbor Advisors LLC now owns 78 shares of the medical device company’s stock worth $26,000 after purchasing an additional 30 shares during the period. Kings Point Capital Management purchased a new stake in Cooper Companies in the second quarter worth about $27,000. Evolution Wealth Advisors LLC purchased a new stake in Cooper Companies in the second quarter worth about $34,000. Finally, NumerixS Investment Technologies Inc purchased a new stake in Cooper Companies in the second quarter worth about $34,000. Institutional investors and hedge funds own 96.10% of the company’s stock.
About Cooper Companies
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Recommended Story: Cost of Equity For A Business, Investors
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.